Table 2.
Performance of developed models identifying platinum-resistant cases.
| No. of Variables | List | Machine Learning |
AUC | Sensitivity | Specificity | Balanced Accuracy |
Threshold |
|---|---|---|---|---|---|---|---|
| 1 | FIGO stage | LR | 0.556 | 1.000 | 0.111 | 0.556 | 0.025 |
| RF | 0.500 | 0 | 1.000 | 0.500 | 0 | ||
| SVM | 0.556 | 1.000 | 0.167 | 0.583 | 0.241 | ||
| DNN | 0.558 | 1.000 | 0.122 | 0.561 | 0.214 | ||
| 1 | Residual tumor size after PDS/IDS | LR | 0.586 | 0.605 | 0.564 | 0.584 | 0.172 |
| RF | 0.500 | 0 | 1.000 | 0.500 | 0 | ||
| SVM | 0.586 | 0.605 | 0.564 | 0.584 | 0.295 | ||
| DNN | 0.587 | 0.605 | 0.564 | 0.584 | 0.355 | ||
| 2 | FIGO stage + Residual tumor size after PDS/IDS | LR | 0.611 | 0.605 | 0.570 | 0.588 | 0.203 |
| RF | 0.500 | 0 | 1.000 | 0.500 | 0 | ||
| SVM | 0.611 | 0.605 | 0.570 | 0.588 | 0.309 | ||
| DNN | 0.611 | 0.605 | 0.570 | 0.588 | 0.252 | ||
| 6 | Age + Serum CA125 levels * + NAC + Pelvic LN status + Involvement of pelvic tissue other than uterus and tube + Involvement of small bowel and mesentery | LR | 0.741 | 0.778 | 0.622 | 0.700 | 0.175 |
| RF | 0.738 | 0.538 | 0.887 | 0.713 | 0.185 | ||
| SVM | 0.733 | 0.731 | 0.745 | 0.738 | 0.232 | ||
| DNN | 0.721 | 0.857 | 0.556 | 0.706 | 0.357 | ||
| 7 | Age + Serum CA125 levels * + NAC + Pelvic LN status + Involvement of pelvic tissue other than uterus and tube + Involvement of small bowel and mesentery + FIGO stage | LR | 0.748 | 0.920 | 0.476 | 0.698 | 0.141 |
| RF | 0.704 | 0.800 | 0.524 | 0.662 | 0.034 | ||
| SVM | 0.745 | 0.920 | 0.457 | 0.689 | 0.133 | ||
| DNN | 0.646 | 0.655 | 0.625 | 0.640 | 0.218 | ||
| 7 | Age + Serum CA125 levels * + NAC + Pelvic LN status + Involvement of pelvic tissue other than uterus and tube + Involvement of small bowel and mesentery + Residual tumor size after PDS/IDS | LR | 0.741 | 0.793 | 0.563 | 0.678 | 0.144 |
| RF | 0.719 | 0.960 | 0.385 | 0.672 | 0.021 | ||
| SVM | 0.740 | 0.517 | 0.883 | 0.700 | 0.259 | ||
| DNN | 0.735 | 0.680 | 0.654 | 0.667 | 0.461 | ||
| 8 | Age + Serum CA125 levels * + NAC + Pelvic LN status + Involvement of pelvic tissue other than uterus and tube + Involvement of small bowel and mesentery + FIGO stage + Residual tumor size after PDS/IDS | LR | 0.738 | 0.769 | 0.648 | 0.708 | 0.211 |
| RF | 0.738 | 0.897 | 0.519 | 0.708 | 0.065 | ||
| SVM | 0.729 | 0.519 | 0.883 | 0.701 | 0.293 | ||
| DNN | 0.740 | 0.852 | 0.561 | 0.707 | 0.088 |
Abbreviations: AUC, area under the receiver operating characteristic curve; CA-125, cancer antigen 125; DNN, deep neural network; FIGO, International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery; LN, lymph node; LR, logistic regression; NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery; RF, random forest; SVM, support vector machine. * Ln-transformed.